Cencora Inc. (COR)vsHong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)
COR
Cencora Inc.
$340.92
-0.14%
HEALTHCARE · Cap: $60.37B
HKPD
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
$0.11
+0.27%
HEALTHCARE · Cap: $5.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 2477075% more annual revenue ($332.77B vs $13.43M). COR leads profitability with a 0.8% profit margin vs -8.5%. COR earns a higher WallStSmart Score of 62/100 (C+).
COR
Buy62
out of 100
Grade: C+
HKPD
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-79.9%
Fair Value
$189.81
Current Price
$340.92
$151.11 premium
Intrinsic value data unavailable for HKPD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 86 in profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Growing faster than its price suggests
Generating 2.4B in free cash flow
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.8% margin — thin
Operating margin of 1.4%
Trading at 21.3x book value
Elevated debt levels
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.2% — below average capital efficiency
Revenue declined 31.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, Altman Z-Score, Market Cap. PEG of 0.65 suggests the stock is reasonably priced for its growth.
Bull Case : HKPD
The strongest argument for HKPD centers on Price/Book, Altman Z-Score, Debt/Equity.
Bear Case : COR
The primary concerns for COR are Profit Margin, Operating Margin, Price/Book. Debt-to-equity of 3.84 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.
Bear Case : HKPD
The primary concerns for HKPD are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
COR profiles as a value stock while HKPD is a turnaround play — different risk/reward profiles.
COR is growing revenue faster at 5.1% — sustainability is the question.
COR generates stronger free cash flow (2.4B), providing more financial flexibility.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
COR scores higher overall (62/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Hong Kong Pharma Digital Technology Holdings Limited is a pioneering entity in the biotechnology and digital healthcare sectors, focused on enhancing patient outcomes through innovative pharmaceutical services. By harnessing cutting-edge digital technologies and sophisticated data analytics, the company optimizes drug development and boosts operational efficiencies, positioning itself as a key player in the dynamic healthcare landscape. With a commitment to health technology advancement and strategic collaborations, Hong Kong Pharma is well-equipped to meet the evolving needs of both domestic and international markets while propelling innovation within its extensive service offerings.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?